Medpace Logo

For Immediate Release: April 20, 2017

Mary Kuramoto
513-579-9911 x 12523

Dr. Marco Tangelder Joins Medpace as Senior Medical Director

CINCINNATI, OH — (April 20, 2017) – Medpace has announced that Marco Tangelder has joined Medpace as Senior Medical Director of Medical Affairs. Medpace (MEDP), a scientifically-driven, global full-service clinical research organization (CRO), is unique in its physician-driven approach to clinical research which gives Sponsors the advantage of early and ongoing insight and guidance from therapeutic experts throughout trial design and execution. Medpace medical doctors provide strategic direction for study design and planning, train operational staff, work with primary investigators, provide medical monitoring, and meet with regulatory agencies. Dr. Tangelder joins a team of highly-experienced physicians and will strengthen Medpace’s ability to support global clinical trials.

About Marco Tangelder, MD, PhD
Dr. Marco Tangelder is a clinical epidemiologist by training with over 20 years of academic, pharmaceutical and biotech industry experience, mainly in the development of antithrombotic therapies for a broad range of indications. Prior to joining Medpace, Dr. Tangelder held a number of key roles in various biotechnology and pharmaceutical companies where he was responsible for clinical development initiatives. Dr. Tangelder received both his medical degree and his PhD at the University of Utrecht in the Netherlands.

About Medpace
Medpace is a scientifically-driven, global full-service clinical research organization (CRO) providing Phase I-IV clinical development services for drug, biologic, and device programs. Medpace’s physician-led, high-science, and disciplined operating approach leverages regulatory and therapeutic expertise to accelerate the global development of safe and effective medical therapeutics across all major areas including hematology and oncology, cardiovascular, metabolic/diabetes, infectious diseases, and neurology and psychiatry.